Catalogue number: | PA1741 |
Price: | $200.00 |
Reactivities: | Human, Mouse, Rat |
Applications: | Immunohistochemistry, Western Blot |
Size: | 100ug/vial |
Gene: | ALK |
Swiss prot: | Q9UM73 |
Form: | Lyophilized |
Format: | Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg Thimerosal, 0.05mg NaN3. |
Storage temp: | At -20 degree C for one year. After reconstitution, at 4 degree C for one month. It can also be aliquotted and stored frozen at -20 degree C for a longer time.Avoid repeated freezing and thawing. |
Scientific background: | ALK(Anaplastic lymphoma kinase) also known as ALK tyrosine kinase receptor or CD246 (cluster of differentiation 246) is an enzyme that in humans is encoded by the ALK gene. The ALK gene is mapped on 2p23.2-p23.1. Expressed in the small intestine, testis, and brain but not in normal lymphoid cells, ALK shows greatest sequence similarity to the insulin receptor subfamily of kinases. ALK plays an important role in the development of the brain and exerts its effects on specific neurons in the nervous system. The deduced amino acid sequences reveal that ALK is a novel receptor tyrosine kinase having a putative transmembrane domain and an extracellular domain. In Drosophila, localized Jeb activates Alk and the downstream Ras/mitogen-activated protein kinase cascade to specify a select group of visceral muscle precursors as muscle-patterning pioneers. Functional RNA interference screening on a set of these transcriptional targets revealed that CEBPB and BCL2A1 were absolutely necessary to induce cell transformation and/or to sustain growth and survival of ALK-positive ALCL cells. One particularly informative case presented a high-level gene amplification that was strictly limited to ALK, indicating that this gene may contribute on its own to neuroblastoma development. Mutated ALK proteins were overexpressed, hyperphosphorylated, and showed constitutive kinase activity. The knockdown of ALK expression in ALK-mutated cells, but also in cell lines overexpressing a wildtype ALK, led to a marked decrease of cell proliferation. |
References: | 1.Benharroch, D., Meguerian-Bedoyan, Z., Lamant, L., Amin, C., Brugieres, L., Terrier-Lacombe, M.-J., Haralambieva, E., Pulford, K., Pileri, S., Morris, S. W., Mason, D. Y., Delsol, G. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 91: 2076-2084, 1998. 2.Chen, Y., Takita, J., Choi, Y. L., Kato, M., Ohira, M., Sanada, M., Wang, L., Soda, M., Kikuchi, A., Igarashi, T., Nakagawara, A., Hayashi, Y., Mano, H., Ogawa, S. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455: 971-974, 2008. 3.Englund, C., Loren, C. E., Grabbe, C., Varshney, G. K., Deleuil, F., Hallberg, B., Palmer, R. H. Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion. Nature 425: 512-516, 2003. |
Additional info: | A synthetic peptide corresponding to a sequence at the C-terminal of human ALK, identical to the related rat and mouse sequences. |